A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 168
- Population
- ALL · 55 Years to 80 Years
- Duration
- 2019-10-01 to 2022-07-31
- Intervention
- Aflibercept (CinnaGen Co, Iran); Aflibercept (Regeneron, USA)
- Comparator
- Aflibercept (Regeneron, USA)
- Outcomes measured
- The proportion of patients achieving maintaining vision at week 52 — At week 52; Mean changes in the Best-Corrected Visual Acuity Index from week 0 to week 52 — Baseline and at week 52; The percentage of patients who have increase of ≥15 score in ETDRS at week 52 compared to week 0 — Baseline and at week…; The mean change in National Eye Institute Visual Function Questionnaire (NEI VFQ-25) at week 52 compared to week 0 — Ba…; Mean changes in central retinal thickness at week 52 compared to the screening visit — Baseline and at week 52; The percentage of patients without intra-retinal fluid and subretinal fluid at week 52 — Baseline and at week 52; Number of participants with Adverse Events (AEs) — Baseline up to Week 52
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.